Compares heart rhythm procedure with medicines in atrial fibrillation with CRT device
Compares a heart procedure with medicines in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation
Key facts
- Where
- Brno, České Budějovice, Liberec, Olomouc, Ostrava, Prague, and Třinec, CzechiaSee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with permanent or recurrent persistent atrial fibrillation who have had a CRT device for over 6 months. Heart rate control on medicine is not good enough.
- Age
- Over 18 and under 85 years (the record lists 18 to 85 years).
- Sex
- All sexes can join.
- Disease stage
- Permanent atrial fibrillation, or recurrent persistent atrial fibrillation with at least one emergency visit or hospital stay in the past year.
- Earlier treatment
- Must have had CRT (a biventricular pacemaker/defibrillator or conduction system pacemaker) for more than 6 months. Must be on optimized heart failure medicine and heart rate control medicine.
- Biomarker or test result
- For permanent AF: BiVP% plus VPC% above 85% and below 99% for at least 1 month while on optimum medicine.
Main reasons for not taking part
- Heart attack or bypass surgery less than 3 months ago
- Technical failure of the CRT system
- Intentional preference for the heart's own AV conduction
- Expected survival less than 1 year
- Dementia (mini-mental test below 23 points)
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05776797, who can take part
Where in Czechia
- St. Anne's University Hospital BrnoBrno, CzechiaTaking people
- University Hospital BrnoBrno, CzechiaTaking people
- Hospital České BudějoviceČeské Budějovice, CzechiaTaking people
- Regional Hospital LiberecLiberec, CzechiaTaking people
- University Hospital OlomoucOlomouc, CzechiaTaking people
- University Hospital OstravaOstrava, CzechiaTaking people
- Institute of Clinical and Experimental MedicinePrague, CzechiaTaking people
- Military University Hospital PraguePrague, CzechiaTaking people
- Hospital Podlesí, Inc.Třinec, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Ostrava
- Trial code
- NCT05776797
- Record updated
- 8 June 2023
- Original description
A study comparing atrioventricular junction ablation (AVJA) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) with suboptimal heart rate control on optimum medication.Read full original descriptionShow less
AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation
A study comparing atrioventricular junction ablation (AVJA) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) with suboptimal heart rate control on optimum medication.
Inclusion: Treatment with CRT using either a biventricular pacemaker/defibrillator or conduction system pacemaker (>6 months); Diagnosis of AF and classified as: permanent AF or recurrent persistent AF, requiring emergency visits and/or hospitalizations (at least one in recent year); Optimized HF medical treatment and rate control medication; BiVP% + ventricular premature complex (VPC%) <99% and >85% during the minimum period of 1 month while already on optimum medical therapy (applicable only for patients with permanent AF); Age >18 and <85 years; Signed informed consent.
Exclusion: myocardial infarction (MI) or coronary artery bypass graft (CABG) <3 months; Technical failure of the CRT system; Other significant comorbidities and/or conditions that interfere with the proper conduction of the trial; Dementia as assessed by mini-mental test (<23 points); Intentional preference for spontaneous AV conduction; Expected survival <1 year.